Comparison · NCT02354508-sae
Up-titrated to Pasireotide LAR 60 mg vs Pasireotide LAR Overall: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Up-titrated to Pasireotide LAR 60 mg vs Pasireotide LAR Overall: serious adverse events. Trial comparisons, record NCT02354508-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02354508-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0652 | 0.0302 | 0.135 | wilson | |
| Risk in group 2 | 0.0976 | 0.0567 | 0.163 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0323 | -0.106 | 0.0486 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.668 | 0.261 | 1.71 | log | |
| Odds ratio, group 1 over group 2 | 0.645 | 0.233 | 1.79 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Up-titrated to Pasireotide LAR 60 mg than on Pasireotide LAR Overall | 30.9 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Up-titrated to Pasireotide LAR 60 mg | Patients not achieving biochemical control and were up-titrated to pasireotide LAR 60 mg. | 6 | 92 | EG000 |
| Group 2 | Pasireotide LAR Overall | This is the sum total of participants in under the previous treatments in the Core phase: lanreotide 120 mg, octreotide 30 mg or octreotide 40 mg or who were treated with at least one dose of pasireotide LAR in the extension phase | 12 | 123 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Adverse events (AEs) were collected from first dose of study treatment until end of study treatment plus 84 days post treatment, up to maximum duration of 76 weeks.
Source ClinicalTrials.gov
Trial
- Title
- Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues
- NCT number
- NCT02354508
- Phases
- PHASE3
- Conditions
- Acromegaly
- Interventions
- Pasireotide LAR
- Lead sponsor
- Novartis Pharmaceuticals
- Results first posted
- 2019-12-04
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02354508?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02354508-sae